Showing 1 - 19 results of 19 for search 'Macaya Douoguih', query time: 0.05s
Refine Results
-
1
-
2
Prediction of long-term humoral response induced by the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola by Marie Alexandre, Mélanie Prague, Chelsea McLean, Viki Bockstal, Macaya Douoguih, Rodolphe Thiébaut, for the EBOVAC 1 and EBOVAC 2 Consortia
Published 2023-11-01
Article -
3
Assessments of different batches and dose levels of a two-dose Ad26.ZEBOV and MVA-BN-Filo vaccine regimen by Viki Bockstal, Auguste Gaddah, Neil Goldstein, Georgi Shukarev, Stephan Bart, Kerstin Luhn, Cynthia Robinson, Dickson Anumendem, Maarten Leyssen, Macaya Douoguih
Published 2021-12-01
Article -
4
Lot-to-lot consistency, immunogenicity, and safety of the Ad26.ZEBOV, MVA-BN-Filo Ebola virus vaccine regimen: A phase 3, randomized, double-blind, placebo-controlled trial by Neil Goldstein, Chelsea McLean, Auguste Gaddah, Joachim Doua, Babajide Keshinro, Linda Bus-Jacobs, Jenny Hendriks, Kerstin Luhn, Cynthia Robinson, Macaya Douoguih
Published 2024-12-01
Article -
5
Safety and immunogenicity of Ad26.COV2.S in adolescents: Phase 2 randomized clinical trial by Jelena Tica, Veronica V. Rezelj, Benoit Baron, Vitalija van Paassen, Javier Zaidman, Lee Fairlie, Gert Scheper, Mathieu Le Gars, Frank Struyf, Macaya Douoguih, Javier Ruiz-Guiñazú
Published 2025-12-01
Article -
6
Durable natural killer cell responses after heterologous two-dose Ebola vaccination by Helen R. Wagstaffe, Giada Susannini, Rodolphe Thiébaut, Laura Richert, Yves Lévy, Viki Bockstal, Jeroen N. Stoop, Kerstin Luhn, Macaya Douoguih, Eleanor M. Riley, Christine Lacabaratz, Martin R. Goodier
Published 2021-01-01
Article -
7
NK Cell Subset Redistribution and Antibody Dependent Activation after Ebola Vaccination in Africans by Helen R. Wagstaffe, Omu Anzala, Hannah Kibuuka, Zacchaeus Anywaine, Sodiomon B. Sirima, Rodolphe Thiébaut, Laura Richert, Yves Levy, Christine Lacabaratz, Viki Bockstal, Kerstin Luhn, Macaya Douoguih, Martin R. Goodier
Published 2022-05-01
Article -
8
Safety and Humoral Immunogenicity of Different Dose Levels of Ad26.COV2.S as a 2-Dose Regimen in COVID-19 Vaccine-Naïve Healthy Adults: A Phase 3 Randomized Clinical Trial by Veronica V. Rezelj, Fred Paddenburg, Marie Enajite Diegbe, Julius Nangosyah, Emil C. Reisinger, Weihong Hu, Carla Truyers, Gert Scheper, Mathieu Le Gars, Jenny Hendriks, Frank Struyf, Macaya Douoguih, Hanneke Schuitemaker, Javier Ruiz-Guiñazú
Published 2024-10-01
Article -
9
Safety and immunogenicity of 3 formulations of a Sabin inactivated poliovirus vaccine produced on the PER.C6® cell line: A phase 2, double-blind, randomized, controlled study in in... by Anna Lisa Ong-Lim, Georgi Shukarev, Mitzi Trinidad-Aseron, Delia Caparas-Yu, Astrid Greijer, Michel Duchene, Gert Scheper, Vitalija van Paassen, Mathieu Le Gars, Conor P. Cahill, Hanneke Schuitemaker, Macaya Douoguih, Jeanne-Marie Jacquet
Published 2022-11-01
Article -
10
Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola by Viki Bockstal, Maarten Leyssen, Dirk Heerwegh, Bart Spiessens, Cynthia Robinson, Jeroen N. Stoop, Ramon Roozendaal, Thierry Van Effelterre, Auguste Gaddah, Griet A. Van Roey, Laura Solforosi, Roland Zahn, Benoit Callendret, Jenny Hendriks, Kerstin Luhn, Macaya Douoguih, Hanneke Schuitemaker, Johan Van Hoof
Published 2022-11-01
Article -
11
Persistence of immunological memory as a potential correlate of long-term, vaccine-induced protection against Ebola virus disease in humans by Chelsea McLean, Karin Dijkman, Auguste Gaddah, Babajide Keshinro, Michael Katwere, Macaya Douoguih, Cynthia Robinson, Laura Solforosi, Dominika Czapska-Casey, Liesbeth Dekking, Yvonne Wollmann, Ariane Volkmann, Maria Grazia Pau, Benoit Callendret, Jerry Sadoff, Hanneke Schuitemaker, Roland Zahn, Kerstin Luhn, Jenny Hendriks, Ramon Roozendaal
Published 2023-09-01
Article -
12
Long-Term Clinical Safety of the Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: A Prospective, Multi-Country, Observational Study by Adeep Puri, Andrew J. Pollard, Catherine Schmidt-Mutter, Fabrice Lainé, George PrayGod, Hannah Kibuuka, Houreratou Barry, Jean-François Nicolas, Jean-Daniel Lelièvre, Sodiomon Bienvenu Sirima, Beatrice Kamala, Daniela Manno, Deborah Watson-Jones, Auguste Gaddah, Babajide Keshinro, Kerstin Luhn, Cynthia Robinson, Macaya Douoguih
Published 2024-02-01
Article -
13
First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered i... by Viki Bockstal, Georgi Shukarev, Chelsea McLean, Neil Goldstein, Stephan Bart, Auguste Gaddah, Dickson Anumenden, Jeroen N. Stoop, Anne Marit de Groot, Maria G. Pau, Jenny Hendriks, Stephen C. De Rosa, Kristen W. Cohen, M. Juliana McElrath, Benoit Callendret, Kerstin Luhn, Macaya Douoguih, Cynthia Robinson
Published 2022-01-01
Article -
14
Safety, reactogenicity, and immunogenicity of Ad26.COV2.S co-administered with a quadrivalent standard-dose or high-dose seasonal influenza vaccine: a non-inferiority randomised co... by Gabriela Tapia-Calle, Gloria Aguilar, Nathalie Vaissiere, Carla Truyers, Pedro Ylisastigui, Erik Buntinx, Mathieu Le Gars, Frank Struyf, Gert Scheper, Macaya Douoguih, Javier Ruiz-Guiñazú, Robert Patrizi, Wai Ling, Sanne de Ridder, Marit de Groot, Maria Grazia Pau, Gerald Weidinger, Srividya Pradeep, Nadine Salisch, Sophie Cambre
Published 2025-01-01
Article -
15
Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate by Ramon Roozendaal, Jenny Hendriks, Thierry van Effelterre, Bart Spiessens, Liesbeth Dekking, Laura Solforosi, Dominika Czapska-Casey, Viki Bockstal, Jeroen Stoop, Daniel Splinter, Sarah Janssen, Ben van Baelen, Nadia Verbruggen, Jan Serroyen, Eline Dekeyster, Ariane Volkmann, Yvonne Wollmann, Ricardo Carrion, Luis D. Giavedoni, Cynthia Robinson, Maarten Leyssen, Macaya Douoguih, Kerstin Luhn, Maria Grazia Pau, Jerry Sadoff, An Vandebosch, Hanneke Schuitemaker, Roland Zahn, Benoit Callendret
Published 2020-12-01
Article -
16
Immune response of a two-dose heterologous Ebola vaccine regimen: summary of three African clinical trials using a single validated Filovirus Animal Nonclinical Group enzyme-linked... by Chelsea McLean, Houreratou Barry, Mark Kieh, Zacchaeus Anywaine, Baimba Tapima Rogers, Seydou Doumbia, Sodiomon B. Sirima, Alimamy Serry-Bangura, Abdoul Habib Beavogui, Auguste Gaddah, Michael Katwere, Jenny Hendriks, Babajide Keshinro, Serge Eholie, Hannah Kibuuka, Stephen B. Kennedy, Omu Anzala, Mohamed Samai, Eric D'Ortenzio, Bailah Leigh, Samba Sow, Rodolphe Thiébaut, Brian Greenwood, Deborah Watson-Jones, Macaya Douoguih, Kerstin Luhn, Cynthia Robinson
Published 2023-05-01
Article -
17
Safety and Immunogenicity of an Accelerated Ebola Vaccination Schedule in People with and without Human Immunodeficiency Virus: A Randomized Clinical Trial by Julie A. Ake, Kristopher Paolino, Jack N. Hutter, Susan Biggs Cicatelli, Leigh Anne Eller, Michael A. Eller, Margaret C. Costanzo, Dominic Paquin-Proulx, Merlin L. Robb, Chi L. Tran, Lalaine Anova, Linda L. Jagodzinski, Lucy A. Ward, Nicole Kilgore, Janice Rusnak, Callie Bounds, Christopher S. Badorrek, Jay W. Hooper, Steven A. Kwilas, Ine Ilsbroux, Dickson Nkafu Anumendem, Auguste Gaddah, Georgi Shukarev, Viki Bockstal, Kerstin Luhn, Macaya Douoguih, Cynthia Robinson
Published 2024-05-01
Article -
18
Protocol for a phase 3 trial to evaluate the effectiveness and safety of a heterologous, two-dose vaccine for Ebola virus disease in the Democratic Republic of the Congo by Deborah Watson-Jones, Shelley Lees, Brian Greenwood, Daniel G Bausch, Peter G Smith, Chrissy H Roberts, Nathalie Imbault, Anton Camacho, W John Edmunds, Eric Delaporte, Melanie Saville, John Johnson, Ira M Longini, Hugo Kavunga-Membo, Rebecca F Grais, Steve Ahuka, Natalie Roberts, Edward M Choi, Tansy Edwards, Maarten Leyssen, Bart Spiessens, Kerstin Luhn, Macaya Douoguih, Richard Hatchett, Jean-Jacques Muyembe, W John Edmunds, Daniela Manno, Rebecca Grais, Susan Rattigan, Grace Mambula, Patient Mumbere Kighoma, Marie Burton, Gerald Voss
Published 2022-03-01
Article -
19
Neutralizing antibody correlate of protection against severe-critical COVID-19 in the ENSEMBLE single-dose Ad26.COV2.S vaccine efficacy trial by Lindsay N. Carpp, Ollivier Hyrien, Youyi Fong, David Benkeser, Sanne Roels, Daniel J. Stieh, Ilse Van Dromme, Griet A. Van Roey, Avi Kenny, Ying Huang, Marco Carone, Adrian B. McDermott, Christopher R. Houchens, Karen Martins, Lakshmi Jayashankar, Flora Castellino, Obrimpong Amoa-Awua, Manjula Basappa, Britta Flach, Bob C. Lin, Christopher Moore, Mursal Naisan, Muhammed Naqvi, Sandeep Narpala, Sarah O’Connell, Allen Mueller, Leo Serebryannyy, Mike Castro, Jennifer Wang, Christos J. Petropoulos, Alex Luedtke, Yiwen Lu, Chenchen Yu, Michal Juraska, Nima S. Hejazi, Daniel N. Wolfe, Jerald Sadoff, Glenda E. Gray, Beatriz Grinsztejn, Paul A. Goepfert, Linda-Gail Bekker, Aditya H. Gaur, Valdilea G. Veloso, April K. Randhawa, Michele P. Andrasik, Jenny Hendriks, Carla Truyers, An Vandebosch, Frank Struyf, Hanneke Schuitemaker, Macaya Douoguih, James G. Kublin, Lawrence Corey, Kathleen M. Neuzil, Dean Follmann, Richard A. Koup, Ruben O. Donis, Peter B. Gilbert, On behalf of the Immune Assays Team, the Coronavirus Vaccine Prevention Network (CoVPN)/ENSEMBLE Team, the United States Government (USG)/CoVPN Biostatistics Team
Published 2024-11-01
Article